All In MedTech

FDA Clearance Tracker · P850020-S019

PROSORBA COLUMN

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 14, 2004 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 14, 2004

Approved

Time to decision

180 days

Received Oct 17, 2003. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Unclassified

The decision

FDA number
P850020-S019
Device name
PROSORBA COLUMN
Applicant location
Waltham, MA
Received
Oct 17, 2003
Decided
Apr 14, 2004
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P850020

Device type

Device class
Unclassified

Every decision under product code LKN

FDA's approval statement

As written in FDA's record.

APPROVAL FOR SEVERAL CHANGES TO THE RA-4 POST-APPROVAL STUDY PROTOCOL. SPECIFICALLY, THESE ARE: 1) A CHANGE IN INCLUSION CRITERION 6 TO ALLOW THE ENROLLMENT OF PATIENTS WHO HAVE BEEN ON METHOTREXATE (>= 15 MG/WEEK) FOR AT LEAST THREE MONTHS PRIOR TO SCREENING, RATHER THAN SIX MONTHS PRIOR TO SCREENING; 2) THE ADDITION OF AN INCLUSION CRITERION TO ALLOW THE ENROLLMENT OF PATIENTS WHO HAVE HAD TOXICITY TO METHOTREXATE AT A DOSE OF >= 15 MG/WEEK IF THEY CAN BE ON A DOSE OF 12.5 MG/WEEK; 3) THE INCLUSION OF PATIENTS RECEIVING CONCOMITANT TREATMENT WITH OTHER DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS); AND 4) THE INCLUSION OF PATIENTS WITH 12 OR MORE JOINTS TENDER OR PAINFUL ON MOTION OR PRESSURE, RATHER THAN 16 SUCH JOINTS.

Source documents

Other decisions for Fresenius Hemocare, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.